STOCK TITAN

Teknova to Participate in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Alpha Teknova, a key provider of critical reagents for biopharmaceuticals, will participate in the BTIG MedTech, Digital Health, Life Science, and Diagnostic Tools Conference from February 15-17, 2022. The company's President, Stephen Gunstream, and CFO, Matt Lowell, will host a virtual fireside chat on February 17 at 1:00 p.m. ET. They will discuss company highlights, market trends, and growth drivers. Teknova specializes in custom products for bioprocessing, offering high-quality reagents for applications like cell and gene therapy.

Positive
  • None.
Negative
  • None.

HOLLISTER, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference.

BTIG MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 15 - 17, 2022
Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, will be participating in a virtual fireside chat at 1:00 p.m. ET, on Thursday, February 17, 2022. Gunstream and Lowell plan to discuss Company highlights, market trends, key growth drivers, and long-term market opportunities. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About Teknova
Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization. For more information about Teknova, visit www.teknova.com.


FAQ

When will Alpha Teknova participate in the BTIG conference?

Alpha Teknova will participate in the BTIG MedTech, Digital Health, Life Science, and Diagnostic Tools Conference from February 15-17, 2022.

Who will represent Teknova at the BTIG conference?

Stephen Gunstream, President and CEO, and Matt Lowell, CFO, will represent Teknova.

What topics will Teknova discuss during the fireside chat?

During the fireside chat, Teknova will discuss company highlights, market trends, key growth drivers, and long-term market opportunities.

What is Teknova's focus in the biopharmaceutical sector?

Teknova focuses on providing custom products and reagents for bioprocessing, including applications in cell and gene therapy.

How can one listen to Teknova's virtual chat at the conference?

To listen to the live event, participants need to contact their BTIG representative.

Alpha Teknova, Inc.

NASDAQ:TKNO

TKNO Rankings

TKNO Latest News

TKNO Stock Data

419.53M
10.58M
9.33%
80.45%
0.51%
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
HOLLISTER